HIMS
The FDA just opened the door a crack
Hims & Hers got a nice shot of adrenaline on April 16 after the FDA signaled it would review restrictions on certain peptides. That matters because the company has been leaning into compounded GLP-1 alternatives and other peptide-related offerings like they’re the next big wellness buffet.
Why investors care
The FDA’s newly released documents show it revised its 503A ingredient categories on April 15 and plans to drop 12 peptides from Category 2, which is basically the agency’s “these have some serious side-eye attached” bucket. Translation: the regulatory fog around peptides may be lifting, at least a little.
The agency also set a Pharmacy Compounding Advisory Committee meeting for July 23-24 to review seven peptides for possible inclusion on the 503A bulks list. That list is the gatekeeper for which bulk substances can legally be used in certain compounded drugs. In other words, this is the kind of paperwork that can quietly make or break business models.
The lineup is… very biotech-core
The review list includes names that sound like either lab compounds or Star Wars droids:
- BPC-157
- KPV
- TB-500
- MOTs-C
- emideltide
- semax
- epitalon
The potential use cases are just as wide-ranging: ulcerative colitis, wound healing, obesity, migraine, chronic insomnia, and opioid withdrawal. So yes, this is part regulatory news, part “maybe the future of medicine is also a supplement aisle.”
Big picture
For Hims, this is less about a single FDA memo and more about optionality. If peptide restrictions loosen, the company could have more room to grow its compounded-drug playbook. If not, the stock’s current sugar high may fade fast.